Current Status Regarding Immunosuppressive Treatment in Patients after Renal Transplantation.
This review summarizes the current status of immunosuppressive therapy after renal transplantation, where personalized triple-drug maintenance based on calcineurin inhibitors, corticosteroids, and antiproliferative agents remains standard, with ongoing efforts to develop regimens that reduce toxicity and side effects.
Background
Renal transplantation is the best treatment for end-stage renal failure, but recipients require lifelong immunosuppressive therapy to avoid rejection and prolong graft function. The choice of immunosuppressive drugs depends on factors including time since transplantation (induction versus maintenance), the underlying disease, and the condition of the graft, and protocols vary among centers based on experience.
Key recommendations
Maintenance treatment in renal transplant recipients is mostly based on triple-drug therapy combining calcineurin inhibitors, corticosteroids, and antiproliferative drugs. The review describes the classes of immunosuppressive drugs and their modes of action, organized by induction and maintenance treatment, and emphasizes that immunosuppression must be personalized to the individual patient.
Clinical implications
Alongside their desired effects, immunosuppressive drugs carry the risk of significant side effects, driving the search for new drugs and protocols that exert fewer adverse effects while maximizing efficacy and reducing toxicity. The goal is to lower morbidity and mortality and to enable individualized immunosuppression for renal transplant recipients of all ages, with the review also covering complications and other treatment options.
Category
Transplant
Source
Int J Mol Sci
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.